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The systemic therapy of many curd~ou~cu~r diseases is often hampered by uduerse drug effects. 
The present paper examines the use of ~ontro~~d release implunts as a mean for optimizing drug 
concentrations at the affected site in the ~ard~v~~u~r system, while using a relatively low sys- 
temic dose. Controlled release systems have been prepared by combining a drug of choice with 
either a non-degradable polymer, such as a silicone rubber, polyurethane, and ethylene vinyl- 
acetate, or a biodegradable compound such aspoly(glycolic-lactic acid) or a high molecular weight 
polyanhydride. Controlled release matrices containing ethylenehydroxydiphosphonate (EHDP), 
when implanted next to a bioprosthetic heart valve leaflet, prevented pathologic calcification. 
Similarly, controlled release matrices containing lidocaine-HCl have been used experimentally as 
epicardial implants to convert ventricular taehycardia to normal sinus rhythm in dogs. A matrix 
system containing gentamic~n has been used by others [35] to prevent experimental valvular 
endo~ardit~. stir workers have used a dexamet~one-rele~ing ~urd~c pacing lead in clinical 
studies, to prevent scar tissue format~n, which leads to e~vated e~~trical~~~ thres~~ [15,16]. 
Future controlled release systems for cardiovascular use will very likely incorporate innovative 
design features including: a reservoir configuration to replenish or change drug therapy, modu- 
latable drug release to vary drug dosing as desired, and closed-loop feedback to increase or decrease 
release rates in response to disease status. 
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INTRODUCTION 
The therapy of a variety of cardiovascular 
diseases is often hampered by adverse drug ef- 
fects. For example, antiarrhythmic therapy us- 
ing drugs such as propanolol, lidocaine, or 
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amiodarone is often complicated by drug-re- 
lated cardiac and systemic adverse effects [l- 
31. The use of controlled release implants is a 
potential way to avoid this type of problem and 
optimize treatment. The general strategy to be 
considered in this paper is that of implanting a 
drug delivery device at the site of an actual or 
potential pathologic process within the cardio- 
vascular system. Local administration of a drug 
by this means is hypothesized to produce high 
regional concentrations, but relatively low net 
systemic doses. Thus, this approach would op- 
timize therapy where it is needed and avoid high 
level drug exposure. 
For the purpose of this paper controlled re- 
lease will be defined as drug administration by 
means of an inert polymeric drug carrier. The 
drug may be incorporated into a controlled re- 
lease system either as a dispersion in a mono- 
lithic matrix, or in the core of a reservoir. Ma- 
trices are typically formed with dispersions of 
uniform drug particles in biocompatible poly- 
meric materials. Examples of nondegradable 
matrix polymers which have been widely used 
include: ethylene vinylacetate [ 4-61, silicone 
rubber [ 7-91, and polyurethane [lo]. It is often 
advantageous to utilize biologically degradable 
matrix materials for controlled release im- 
plants, and this approach has been carried out 
using matrices composed of compounds such as 
poly (glycolic-lactic ) acid [ 111, polyanhy- 
drides [ 12 1, and poloxamers [ 131. 
Reservoir configured controlled release sys- 
tems have been less thoroughly investigated 
than matrices. However, reservoir systems of- 
fer a number of advantages including the abil- 
ity to vary drug dosages, replenish drug sup- 
plies, or change therapy to a new pharmacologic 
agent. Controlled release reservoirs have been 
used as long-term (5 year) birth control im- 
plants [ 141, and this general strategy utilizing 
reservoirs will very likely be useful for cardio- 
vascular disease as well. 
Controlled release systems may be used to 
deliver a wide array of pharmacologic agents and 
macromolecules. This paper will describe in de- 
tail below the use of controlled release matrices 
for local administration of such diverse com- 
pounds as diphosphonates [ 5-71, steroids 
[ 15,161, and antiarrhythmic compounds [lo]. 
In addition, the work of Langer and Folkman 
[ 41, has demonstrated the potential for con- 
trolled release systems to deliver peptides and 
proteins over sustained periods ranging from 
weeks to months with intact biologic activity. 
Also of note, is the potential for varying the du- 
ration of controlled release depending upon the 
drug-polymer formulation [6,7] used and on 
the geometry utilized as well [17,18]. For ex- 
ample, hemispheric configured controlled re- 
lease systems maintain a nearly constant drug 
release pattern while rectangular or cylindrical 
configured systems have a rather accelerated 
early phase of release followed by a continuous 
decline in drug release rates [17,X]. In addi- 
tion, using drug salts of relatively lower solu- 
bility [7], as well as rate-limiting membranes 
[7], it is possible to sustain controlled release 
durations for periods of months to years. How- 
ever, using either biodegradable systems or thin 
elastomeric films, release durations can also be 
made as brief as desirable. 
Initial interest in the local administration of 
drugs in the cardiovascular system can be traced 
to the work of Mautz in the 1930s [ 191. This 
investigator administered procaine into the 
pericardial sack of dogs and demonstrated a re- 
duction in ventricular irritability. The pioneer- 
ing of Folkman and Long [20] led to the first 
use of a controlled release system as a cardiac 
implant in the 1960s. These investigators fash- 
ioned silicone rubber reservoirs filled with var- 
ious cardiac chronotropes. The silicone rubber 
reservoirs were demonstrated to function as 
pharmacologic pacemakers when they were 
loaded with agents such as thyroid hormone or 
norepinephrine and placed within the myocar- 
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dium. Thus, these prior investigations demon- 
strated the potential for drug administration 
directly to the heart and were fundamental to 
subsequent discoveries. 
MATERIALS AND METHODS 
Poly (dimethyl siloxane) s (SIL) used for 
controlled release studies were medical grade 
Silastics (Dow Corning, Midland, MI). Ethyl- 
ene vinylacetate was obtained from DuPont 
(Wilmington, DE), and the polyurethanes used 
in our studies were either Tecoflex 80A or 
Thyomer (Thermedics, Woburn, MA). Etha- 
nehydroxydiphosphonate (EHDP) as the di- 
sodium salt was provided by Norwich Eaton, 
Inc. (Norwich, NY ). Lidocaine HCl was pro- 
vided by Abbott Laboratories (Chicago, IL). 
Other chemicals used were reagent grade as ob- 
tained from Sigma (st. Louis, MO). Bovine 
pericardium or porcine aortic valves were ob- 
tained fresh at slaughter and pretreated with 
glutaraldehyde as previously described [ 5-71. 
Pretreated tissue was stored for at least 3 weeks 
or more prior to use. 
Controlled release matrices were formulated 
as either drug dispersions in solid prepolymer 
[ 5-91 or as drug-polymer solutions in dimethy- 
lacetamide for certain polyurethane studies 
[lo]. Matrices were cast in the desired geomet- 
ric shape and were allowed to polymerize or so- 
lidify or both depending upon the formulation. 
In vitro release of controlled release matrices 
was carried out in an excess of a physiologic 
buffer (pH 7.4, 0.05 A4 HEPES) at 37°C with 
frequent sampling of the releasing buffer for ra- 
diolabeled ( 14C ) drug [ 5-101. 
Rats used in the subdermal bioprosthetic im- 
plant calcification experiments were 3 week old 
male Sprague Dawley-CD (Charles River Inc., 
Burlington, MA) [ 5-71. Sheep used in the open 
heart tricuspid valve replacement studies were 
male Suffolks, ages 5 to 7 months, weighing 40 
to 50 kg at the time of surgery [ 8,9]. Bioprosth- 
etic tissue explant assessment for calcification 
and morphology was carried out as previously 
described. The dogs used in the arrhythmia ex- 
periments were male mongrels ranging in weight 
from 10 to 20 kg. The animals were monitored 
for electrocardiographic changes throughout 
these experiments [lo], and periodic blood 
sampling for antiarrhythmic drug levels were 
obtained as well [lo]. 
RESULTS AND DISCUSSION 
Preventing experimental cardiovascular 
calcification 
The formation of calcium phosphate depos- 
its in blood vessels and heart valves is a com- 
mon pathologic process complicating both pri- 
mary cardiovascular disease and cardiovascular 
implant surgery [ 211. There has been virtually 
no progress in the therapy of established car- 
diovascular calcifications, and prevention of the 
formation of these lesions has been compli- 
cated by side effects of the anticalcification 
agents. The bulk of the work in this area has 
focused on the use of diphosphonate com- 
pounds for prevention of experimental bio- 
prosthetic heart valve calcification (Table 1) . 
Valvular bioprostheses are prepared with 
either glutaraldehyde-pretreated porcine aortic 
valves or stent-mounted glutaraldehyde-pre- 
treated bovine pericardium [ 221. These devices 
have been widely used as replacement cardiac 
valves because of their central orifice flow prop- 
erties and relative nonthrombogenicity. How- 
ever, calcification is the chief limiting factor 
leading to the clinical failure of these prostheses 
[ 23,241. Intrinsic calcification occurs deep 
within the cupsal tissue and appears to be due 
to the propensity of the devitalized cells and 
structural protein matrix of glutaraldehyde- 
pretreated tissue to calcify. Excellent experi- 
mental models of this disease have been devel- 
oped using either orthotopic valve replace- 
ments in large animals such as sheep [25] or 
calves [ 261, or subdermal implants in rats [ 26- 
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TABLE 1 
Inhibition of bioprosthetic heart valve leaflet calcification with controlled release ethanehydroxydiphosphonate (EHDP) 







(porcine aortic valve) 
NaEHDP (20% ) in SIL 10 2.3& 0.5 7 
NaEHDP : CaEHDP (20% ) in SIL 10 4.2+ 0.9 7 
Control (no drug) 10 160.0? 9.1 7 
- 7 1.22 0.1 27 
NaEHDP: CaEHDP (30% ) in SIL 5 2.7& 1.0 8 
Control (no drug) 6 41.3 + 14.9 8 
_ 10 2.8* 0.7 28 
“21 day implants using 3 week old male CD rats. 
b150 day implants using 5-7 months old male Suffolk sheep 
281. In either case, the pathologic lesions pro- 
duced have been shown to be comparable to 
those noted in clinico-pathologic specimens 
[26-281. 
Systemic therapy using ethanehydroxydi- 
phosphonate administered to animals with bio- 
prosthetic tissue implants prevents bioprosth- 
etic calcification [ 29,301. The dose required to 
achieve this effect also results in skeletal di- 
phosphonate toxicity and calcium imbalance 
[ 29,301. However, controlled release adminis- 
tration of EHDP incorporated to either ethyl- 
ene vinylacetate matrices [ 5,6] or silicone rub- 
ber matrices [7] resulted in the inhibition of 
bioprosthetic leaflet calcification at a dose of 
sufficiently low so as to avoid toxic side effects. 
Controlled release diphosphonate has been 
demonstrated to be effective in the subdermal 
experimental model 15-71, although this ap- 
proach has not been clearly beneficial in circu- 
latory studies [ 81. A notable aspect of this work 
has been the use of mixtures of the sodium and 
calcium salts of ethanehydroxydiphosphonate 
(EHDP ) [ 7 1. This has facilitated prolonging 
the release duration of the matrix so that a one 
to one mixture of sodium and calcium EHDP 
in a silicone rubber matrix as a 20% loading has 
an extrapolated release duration of more than 
30 years [7,8]. A matrix composed of a 20% 
loading dicalcium EHDP in silicone rubber has 
an extrapolated release duration of more than 
100 years and still maintains drug efficacy in 
the subdermal model [ 71. 
The use of a controlled release matrix in con- 
jugation with a functioning bioprosthetic heart 
valve is very challenging. It is necessary to po- 
sition the controlled release matrix so that the 
drug can enter the heart valve leaflet tissue di- 
rectly without being washed away by circula- 
tion. However, the controlled release matrix 
cannot interfere with the mechanical aspects of 
heart valve function. The strategy that has been 
used to surmount these difficulties has been to 
position the matrix as a periannular implant 
releasing drug to the site of heart valve leaflet 
attachments (Fig. 1). The diffusion of the drug 
would then take place from the attachment 
point into distal leaflets. One obvious limita- 
tion of this approach is the concentration gra- 
dient which must occur from the valve attach- 
ment points to the free edges, which results in 
less drug being present in the most distal as- 
pects of the heart valve. A way around this is to 
preload heart valve leaflets with either a rela- 
tively insoluble diphosphonate salt such as cal- 






’ Release Matrix 
Fig. 1. An illustration of a controlled release matrix con- 
taining ethanehydroxydiphosphonate (EHDP) as a peri- 
annular sewing cushion in a porcine aortic bioprosthetic 
heart valve. Shown is sealing of the non-releasing surfaces 
to direct drug toward’the valve leaflets at their attachment 
points, with drug diffusion proceeding throughout the lea- 
flets. Reproduced with permission from Replacement Car- 
diac Values, edited by E. Bodner and R. Frater, Pergamon 
Press, Elsmford, NY, 1989. 
phosphonate such as aminopropanehydroxy- 
diphosphonate, which binds to residual alde- 
hyde groups [ 32 1. 
Controlled release for cardiac arrhythmias 
Recent work from our laboratory has dem- 
onstrated the feasibility of controlled release 
administration of lidocaine from polyurethane 
matrices into the epicardium in dogs with ex- 
perimental ventricular tachycardia (Fig. 2, Ta- 
ble 2) [lo]. In our initial experiments ventric- 
ular tachycardia was induced with ouabain 
administration and a controlled release matrix 
was placed at a consistent location on the left 
ventricular epicardium [lo]. Conversion of the 
ventricular tachycardia took place by 1.5 min 
and resulted in plasma lidocaine levels which 
roughly were one quarter of those noted with 
the identical drug doses administered intrave- 
nously. Lidocaine, in addition to having severe 
systemic side effects, is also a myocardial de- 
pressant. Therefore, in collaboration with Dr. 
Kim Gallagher of the University of Michigan, 
the effect of epicardial lidocaine on myocardial 
thickening was assessed with implanted son- 
omicrometers [ 33,341. Minimal (10% ) depres- 
sion of ventricular thickening was noted with a 
dose of 7.5 mg/kg of lidocaine. However, when 
doses as low as 0.3 mg/kg were administered 
into the coronary circulation, profound depres- 
sion of thickening (greater than 30%) were 
noted. Thus, epicardial administration of lido- 
Caine with a controlled release matrix takes 
place without adverse effects on cardiac 
function. 
Subsequent investigations have also demon- 
strated the efficacy of epicardial lidocaine 
administration with the controlled release ma- 
trices for another model of experimental ven- 
tricular tachycardia, which was produced with 
rapid subthreshold impulses (cycle length of 50 
ms ) [ 341 administered to epicardial ventricu- 
lar electrodes in dogs. In this model system, 
controlled release lidocaine dosages on the or- 
der of 0.01 mg/kg were effective for conversion 
of ventricular tachycardia to sinus rhythm. It 
should be noted that these doses are approxi- 
mately 100 times below conventional therapeu- 
tic dosages. Although initial investigations with 
this model system focused on lidocaine, subse- 
quent studies have demonstrated efficacy of ep- 
icardial controlled release for a number of other 
antiarrhythmic agents including: procainam- 
ide, amiodarone, verapamil, flecainide, encain- 
ide, and nickel chloride. Ongoing work is inves- 
tigating the use of these matrix systems for 
arrhythmias due to acute ischemia. 
Other uses of cardiovascular controlled 
release 
Cardiac controlled release is currently in 
clinical use with the Medtronic steroid eluting 
pacing catheter. This concept was based on the 
pioneering work of Stokes and his colleagues 
[ 15,161. The use of cardiac pacemakers is fre- 
quently limited due to increases in the electri- 
cal pacing threshold caused by the formation of 
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Polyurethane Matrix 
Fig. 2. An illustration of epicardial placement of a lidocaine HCl polyurethane controlled release matrix on a dog’s heart with 
electrocardiographic conversion of ouabain induced ventricular tachycardia to normal sinus rhythm. Reproduced with per- 
mission from Elsevier Science Publishers (see Ref. 10). 
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6 1.1 io.l 
4 >60 










scar tissue at the pacing electrode tip. In order 
to counteract this phenomenon, Stokes and his 
colleagues formulated a silicone rubber con- 
trolled release system containing dexametha- 
sone [15,16]. This antiinflammatory agent is 
slowly released over many years time from the 
pacing tip of the catheter into the endocardium 
in which the lead is embedded. Drug release at 
this site prevents scar tissue build-up and thus 
results in the maintenance of a relatively low 
electrical threshold for cardiac pacing. Dexa- 
methasone is a potent antiinflammatory ster- 
oid, and thus the drug effect per dose adminis- 
tered is very much optimized. In addition, the 
site specificity of administration of dexameth- 
asone has been maintained by administering the 
drug directly into the myocardium in a config- 
uration which avoids circulatory washout. 
Another example of a different type of car- 
diovascular controlled release system is that of 
Olanof, Anderson, and Jones [35], who dem- 
onstrated successful controlled release of anti- 
biotics to prevent prosthetic valvular endocar- 
ditis in a dog model. These investigators 
dispersed gentamicin into silicone rubber rings 
which were then incorporated in a periannular 
configuration surrounding the sewing cushion 
of a mechanical heart valve prostheses. In vitro 
drug release, and in uiuo release and efficacy 
were documented for preventing bacteremia in 
this dog model. This particular approach would 
be most suitable for cardiac valve replacement 
in the setting of valvular bacterial endocarditis. 
251 
CRITICAL ASPECTS AND FUTURE 
CONSIDERATIONS 
An important limitation of controlled release 
matrices is their finite drug supply. Although it 
is possible for matrix release to be prolonged 
through through the use of rate-limiting mem- 
branes [7] and relatively insoluble drug salts 
[7,8], this approach results in lower net drug 
dosages, which may not be effective for the par- 
ticular disease of interest. Reservoir systems 
offer a number of advantages in this regard. 
Reservoir devices could be assessed percuta- 
neously and the drug concentration may be al- 
tered as needed. Alternatively, the drug supply 
can be replenished or the therapeutic agent 
changed advantageously. Recent work from our 
laboratory has demonstrated the feasibility of 
this appraoch for a controlled release reservoir 
containing ethanehydroxydiphosphonate [ 361. 
Polyurethane reservoirs containing a mixture 
of the sodium and calcium salt demonstrated 
sustained release properties with an extrapo- 
lated release duration of more than five years, 
and yet with anticalcification efficacy in the 
subdermal model [ 361. 
Another important consideration is the fact 
that the controlled release systems described 
thus far in this paper have release rates which 
cannot be altered once the devices have been 
implanted. However, modulation of controlled 
release is possible through the use of either ul- 
trasound [37] or electromagmetism [38]. In 
particular, electromagnetic modulation of con- 
trolled release is a particularly rapid and sen- 
sitive way of increasing or decreasing release 
rates as desirable. Langer and his colleagues 
have demonstrated that the incorporation of 
magnets into polymeric matrices permits mod- 
ulation by an external electromagnetic field. 
The release rate, in fact, has been demon- 
strated to be significantly correlated with mag- 
netic field strengths and the response time of 
their ethylene vinylacetate system was on the 
order of minutes [ 38 1. Thus, for diseases such 
as cardiac arrhythmias where a rapid increase 
or decrease in drug delivery rate would be de- 
sirable, modulated systems such as the electro- 
magnetic approach would be advantageous. 
In addition, it would be most desirable for 
certain cardiovascular diseases to have closed- 
loop feedback responsiveness regulating con- 
trolled release. The best example of a situation 
in which this would be desirable is that of car- 
diac arrhythmias. Cardiac arrhythmias can be 
readily sensed through computer-mediated al- 
gorithms which detect changes in the electro- 
cardiographic patterns. Once these changes 
have been sensed a controlled release matrix, 
such as the electromagnetic one just described, 
could then be triggered and could provide in- 
creasing levels of drug until the arrhythmia had 
subsided. The computer technology needed to 
carry out the sensing and triggering aspects of 
this approach already exists and is being used 
currently in the implantable defibrillator sys- 
tems [39]. What remains to be done is for a 
suitable controlled release formulation to be 
coupled with this existing technology. 
There are other potential future uses for con- 
trolled release for cardiovascular disease. It may 
be advantageous to administer immunosup- 
pressives following cardiac transplantation di- 
rectly into the heart to avoid such complica- 
tions as cyclosporin-mediated hypertension 
[ 401 and encephalopathy [ 411. Controlled re- 
lease matrices might also be advantageous for 
thrombolysis and anticoagulation, if used as in- 
travascular implants. Further, controlled re- 
lease intravascular implants containing free 
radical scavenging enzymes and related agents 
may also one day be therapeutically useful in 
the therapy of ischemic organ damage [ 421. 
CONCLUSION 
Controlled release implants have been dem- 
onstrated to be effective for a number of set- 
tings related to cardiovascular disease. Dexa- 
methasone-silicone rubber matrices for 
preventing excessive scar tissue formation are 
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already in clinical use in a cardiac pacing cath- 
eter configuration. Other successful experi- 
mental uses of controlled release include: pre- 
vention of cardiovascular calcification with 
diphosphonates; therapy of ventricular tachy- 
cardia with lidocaine HCl and other antiar- 
rhythmic agents; and prevention of cardiac 
valve prosthesis endocarditis with an antibiotic 
eluting valve prosthesis sewing cushion. In each 
instance, local drug concentrations are opti- 
mally elevated, while systemic drug exposure is 
relatively low, limiting the possibilities for ad- 
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